A Phase I/II Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs
Categories (click each to see list of all clinical trials associated with that category): Thoracic (ONC)
Current Status: Open
Phase: I (Cancer Control)
Principal Investigator: Sharma, Bhavina
Contact Information:
Michaela Savine
misavine@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT06228326?term=NCT06228326&rank=1#participation-criteria
Summary
Primary:
- To evaluate safety and tolerability of inhaled KB707 monotherapy and combination regimens (e.g., KB707 plus Keytruda [with or without chemotherapy]; KB707 plus docetaxel)
Secondary:
- To evaluate whether the proposed dose ranges include the maximum tolerated dose (MTD) of KB707
- To evaluate the preliminary efficacy of inhaled KB707 monotherapy and in combination regimens by RECIST v1.1
Exploratory:
- To assess the effect of KB707 monotherapy and in combination regimens on circulating immune effectors.
- To evaluate preliminary efficacy of KB707 monotherapy and in combination regimens by iRECIST.